Dimerix Drug's Potential 'Overlooked' By Australian Market, Says Euroz Hartleys
MT Newswires Live
Sep 12
Dimerix's (ASX:DXB) focal segmental glomerulosclerosis drug DMX-200's "blockbuster potential" is being overlooked by the Australian market, said Euroz Hartleys in a Friday note.
The research firm added that over the next 24 months, US development milestones alone could deliver AU$119 million in payments, with a further $56 million tied to first sales, which, combined with existing cash, represents above 80% of Dimerix's current market cap in cash.
Euroz Hartleys has maintained its speculative buy rating with an unchanged price target of AU$1.68.
The company's shares rose 11% in Friday's close of trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.